Blos­somHill rais­es $100M in bid to re­peat founder­s' can­cer suc­cess at Turn­ing Point

Blos­somHill Ther­a­peu­tics has closed a $100 mil­lion Se­ries B to bring three of its on­col­o­gy small mol­e­cules in­to the clin­ic and col­lect ear­ly ef­fi­ca­cy da­ta around the sec­ond half of 2025.

The San Diego biotech was cre­at­ed in 2020 by CEO J. Jean Cui and ex­ec­u­tive chair Y. Pe­ter Li, the co-founders be­hind Turn­ing Point Ther­a­peu­tics. Cui had served as chief sci­en­tif­ic of­fi­cer at Turn­ing Point, hav­ing been the lead in­ven­tor on its re­cent­ly ap­proved lung can­cer drug Aug­ty­ro. She left in mid-2020, pri­or to its $4.1 bil­lion sale to Bris­tol My­ers Squibb in 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER